Endpoints News· Reynald Castaneda·· 4 小时前AI 评分40
Astellas 从 Audax Biosciences 获得临床前 IL-12 肿瘤药物独家选择权
Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences
AI 导读
Astellas 已从澳大利亚生物技术公司 Audax Biosciences 获得一款临床前免疫肿瘤资产的独家许可选择权，该资产为 IL-12 肿瘤药物。交易涉及 285 百万美元。
正文 · 原文
Astellas has taken an exclusive option to license a preclinical immuno-oncology asset from Australian biotech Audax Biosciences.
The deal features $285 million that covers the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news